Literature DB >> 9294627

Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes.

C D Richardson1, C F Donatucci, S O Page, K H Wilson, D A Schwinn.   

Abstract

BACKGROUND: alpha 1-adrenergic receptors (alpha 1 ARs) are important in the dynamic component of benign prostatic hyperplasia (BPH). Currently, several alpha 1AR antagonists are being used in the treatment of BPH.
METHODS: In order to more fully characterize the pharmacology of the alpha 1AR antagonist tamsulosin, we utilized saturation-binding isotherms with [3H] tamsulosin to determine the Kd of this compound at all three cloned alpha 1AR subtypes stably expressed in rat-1 fibroblasts. To confirm these results, we performed competition binding experiments, displacing [125I]HEAT with increasing concentrations of alfuzosin, doxazosin, 5-methyl-urapidil, prazosin, tamsulosin, terazosin, and (+)YM617 (stereoisomer of tamsulosin) in the same clonal cell lines.
RESULTS: [3H]tamsulosin binds to cloned alpha 1AR subtypes with a rank order of affinity of alpha 1a = alpha 1d > alpha 1b. Competition experiments confirmed the relative nonselectivity of alfuzosin, doxazosin, and prazosin, but revealed slight alpha 1b = alpha 1d > alpha 1a selectivity for terazosin, and clear alpha 1a = alpha 1d > alpha 1b for (+)YM617 and tamsulosin([-]YM617); alpha 1a > alpha 1d > alpha 1b selectivity for 5-methyl-urapidil was confirmed.
CONCLUSIONS: We conclude that tamsulosin displays selectivity for alpha 1a and alpha 1d ARs. This selectivity may contribute to the tamsulosin efficacy reported in several recent clinical studies in patients with BPH.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9294627     DOI: 10.1002/(sici)1097-0045(19970915)33:1<55::aid-pros9>3.0.co;2-8

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  27 in total

Review 1.  Alpha1-adrenoceptor subtypes and lower urinary tract symptoms.

Authors:  Debra A Schwinn; Claus G Roehrborn
Journal:  Int J Urol       Date:  2008-03       Impact factor: 3.369

2.  Efficacy of alpha-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2009

3.  The use of alpha-blockers for the treatment of nephrolithiasis.

Authors:  Michael Lipkin; Ojas Shah
Journal:  Rev Urol       Date:  2006

Review 4.  Tamsulosin: an update of its role in the management of lower urinary tract symptoms.

Authors:  Katherine A Lyseng-Williamson; Blair Jarvis; Antona J Wagstaff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  5-HT1A receptor pharmacophores to screen for off-target activity of α1-adrenoceptor antagonists.

Authors:  Tony Ngo; Timothy J Nicholas; Junli Chen; Angela M Finch; Renate Griffith
Journal:  J Comput Aided Mol Des       Date:  2013-04-27       Impact factor: 3.686

Review 6.  Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.

Authors:  Christopher J Dunn; Anna Matheson; Diana M Faulds
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

7.  Differential effects of the enantiomers of tamsulosin and tolterodine on P-glycoprotein and cytochrome P450 3A4.

Authors:  Aneta Doricakova; Dirk Theile; Johanna Weiss; Radim Vrzal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-27       Impact factor: 3.000

8.  Localizations and expressions of alpha-1A, alpha-1B and alpha-1D adrenoceptors in human ureter.

Authors:  Hyoung Keun Park; Eun Young Choi; Byong Chang Jeong; Hyeon Hoe Kim; Byoung Kwon Kim
Journal:  Urol Res       Date:  2007-11-01

Review 9.  The clinical role of alpha-blockers in the treatment of benign prostatic hyperplasia.

Authors:  G M Oades; J D Eaton; R S Kirby
Journal:  Curr Urol Rep       Date:  2000-08       Impact factor: 3.092

Review 10.  A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia.

Authors:  J C Nickel; S Sander; T D Moon
Journal:  Int J Clin Pract       Date:  2008-10       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.